http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113230404-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2023-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2023-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113230404-B |
| titleOfInvention | Use of SAGE1 inhibitors in the preparation of medicines or kits |
| abstract | The invention relates to the field of biotechnology, in particular to the use of SAGE1 inhibitors in the preparation of medicines or kits. The invention provides the use of the SAGE1 inhibitor in the preparation of a medicine or a kit, and the medicine or the kit is used for: regulating the expression level of the SAGE1‑INTS3 complex. SAGE1 provided by the present invention is abnormally activated in various types of human tumors as a tumor-specific antigen, and can form a functional complex with INTS3. The SAGE1-INTS3 complex exists specifically in various tumor cells and tumor tissues, and further It was confirmed that specifically targeting the SAGE1 gene/protein, or targeting the SAGE1-INTS3 complex gene/protein can greatly inhibit the proliferation of SAGE1-positive cancer cells, anchorage-independent growth, and xenograft tumor growth in vivo. |
| priorityDate | 2019-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 264.